Alzheimer's Disease Against A Cancer

Alzheimer's Disease Against A Cancer.
Although a think over in 2012 suggested a cancer narcotize could reverse the thinking and memory problems associated with Alzheimer's disease, three groups of researchers now as they have been unable to duplicate those findings. The teams said their inquiry could have serious implications for patient safety since the drug involved in the study, bexarotene (Targretin), has sombre side effects, such as major blood-lipid abnormalities, pancreatitis, headaches, fatigue, weight gain, depression, nausea, vomiting, constipation and rash address of homeopathic shops in delhi to sell cydonia vulgaris. "Anecdotally, we have all heard that physicians are treating their Alzheimer's patients with bexarotene, a cancer cure-all with stony side effects," said study co-author Robert Vassar, a professor of room and molecular biology at Northwestern University Feinberg School of Medicine, in Chicago.

This wont should be ended immediately, given the failure of three independent research groups to replicate the plaque-lowering junk of bexarotene. The US Food and Drug Administration approved bexarotene in 1999 to boon refractory cutaneous T-cell lymphoma vigrx.shop. Once approved, however, the antidepressant also was available by prescription for "off-label" uses.

The 2012 study suggested that bexarotene was able to instanter reverse the build-up of beta amyloid plaques in the brains of mice. The authors of the monogram study concluded that treatment with the drug might reverse the cognitive and memory problems associated with the incident of Alzheimer's. Sangram Sisodia, a professor of neurosciences at the University of Chicago and a study co-author of the up-to-date research, admitted being skeptical about the initial findings.

"We were surprised and excited - even stunned - when we maiden saw these results presented at a small conference," Sisodia said in a University of Chicago Medical Center message release. "The mechanism of action made some sense, but the affirmation that they could reduce the areas of plaque by 50 percent within three days and by 75 percent in two weeks seemed too avail to be true".

In attempting to duplicate the findings, the research teams found that they were no kidding too good to be true. "We all went back to our labs and tried to confirm these promising findings. We repeated the approve experiments - a standard process in science. Combined results are really substantial in this field.

None of us found anything like what they described in the 2012 paper". Researchers at the University of Chicago, Northwestern University, Massachusetts General Hospital, Washington University in St Louis and the University of Tubingen in Germany reported in the May 24, 2013 affair of the scrapbook Science that they did not find any reduction in beta amyloid plaques during or after healing with bexarotene in three different strains of mice. Bexarotene has never been tested on kinsmen as a treatment for Alzheimer's disease provillus. Currently, there is no cure or effective treatment for the growing condition, which affects an estimated 5,3 million Americans.